Travere Therapeutics, Inc. (TVTX) — Financial statements
Income statement, balance sheet, and cash flow for Travere Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 491↑110.5% | 233↑60.5% | 145↑32.7% | 109↓17.0% | 132 | |
| Cost of Revenue | 10↑33.5% | 8↓32.4% | 11↑159.0% | 4↑15.8% | 4 | |
| Gross Profit | 480↑113.1% | 225↑68.5% | 134↑27.4% | 105↓17.9% | 128 | |
| Operating Expenses | ||||||
| R&D Expenses | 206↓27.1% | 283↑15.4% | 245↑7.8% | 227↑13.0% | 201 | |
| General & Administrative Expenses | 337↑27.7% | 264↓0.5% | 266↑34.4% | 198↑56.4% | 126 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 337↑27.7% | 264↓0.5% | 266↑34.4% | 198↑56.4% | 126 | |
| Other Expenses | 0.00↓100.0% | 2↓78.6% | 11 | 0.00 | 0.00 | |
| Operating Expenses | 543↓1.1% | 549↑5.2% | 522↑22.8% | 425↑29.7% | 327 | |
| Total Costs & Expenses | 554↓0.6% | 557↑4.4% | 533↑24.3% | 429↑29.6% | 331 | |
| Operating Results | ||||||
| Operating Income | -63↑80.6% | -324↑16.6% | -388↓21.4% | -320↓60.4% | -199 | |
| Depreciation & Amortization | 61↑39.5% | 44↑13.0% | 39↑86.0% | 21↑62.6% | 13 | |
| EBITDA | 22↑108.4% | -266↑18.5% | -326↓9.0% | -299↓62.3% | -184 | |
| EBIT | -39↑87.5% | -309↑15.2% | -365↓13.9% | -320↓62.3% | -197 | |
| Interest & Other Income | ||||||
| Net Interest Income | 2↓70.3% | 7↓36.4% | 10↑320.2% | -5↑73.2% | -18 | |
| Interest Income | 13↓28.6% | 18↓18.2% | 22↑246.8% | 6↑214.9% | 2 | |
| Interest Expense | 11↓3.9% | 11↓1.3% | 11↑2.9% | 11↓44.0% | 20 | |
| Non-Operating Income | -24↓67.6% | -14↑37.9% | -23↓7222.6% | 0.33↑114.7% | -2 | |
| Other Income / Expenses | 14↑308.5% | 3↓72.4% | 12↑206.0% | -11↑35.0% | -17 | |
| Income Before Tax | -49↑84.6% | -321↑14.8% | -376↓13.6% | -331↓52.7% | -217 | |
| Income Tax Expense | 0.99↑723.3% | 0.12↓46.2% | 0.22↓28.8% | 0.31↓23.5% | 0.41 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -50↑84.3% | -321↑14.8% | -376↓13.5% | -331↓52.5% | -217 | |
| Net Income from Discontinued Operations | 25↑2801.1% | -0.92↓100.3% | 265↑400.0% | 53↑42.4% | 37 | |
| Net Income | -26↑92.1% | -322↓188.6% | -111↑60.0% | -278↓54.6% | -180 | |
| Bottom-Line Net Income | -26↑92.1% | -322↓188.6% | -111↑60.0% | -278↓54.6% | -180 | |
| EPS (Basic) | -0.56↑86.3% | -4.08↓172.0% | -1.50↑65.7% | -4.37↓45.2% | -3.01 | |
| EPS (Diluted) | -0.56↑86.3% | -4.08↓172.0% | -1.50↑65.7% | -4.37↓45.2% | -3.01 | |
| Weighted Average Shares | 89↑13.1% | 79↑6.2% | 74↑16.5% | 64↑6.6% | 60 | |
| Weighted Average Diluted Shares | 89↑13.1% | 79↑6.2% | 74↑16.5% | 64↑6.6% | 60 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.